Cimetidine therapy does not prevent rebleeding from peptic ulceration

Area of Science:

• Gastroenterology
• Clinical Pharmacology
• Internal Medicine

Background:

• Acute upper gastrointestinal hemorrhage is a significant clinical concern.
• Peptic ulceration is a common cause of upper GI bleeding.
• Effective treatments are crucial for managing peptic ulcer bleeding.

Purpose of the Study:

• To evaluate the efficacy of cimetidine in treating acute upper gastrointestinal hemorrhage caused by peptic ulcers.
• To compare cimetidine therapy with placebo in a prospective, double-blind, controlled trial.

Main Methods:

• A prospective, double-blind, controlled trial involving 105 patients with peptic ulceration-related upper GI bleeding.
• Cimetidine or placebo therapy initiated within 12 hours of admission and continued for 7 days.
• Assessment of transfusion requirements, rebleeding rates, and surgical intervention.

Main Results:

• Cimetidine therapy showed no significant difference compared to placebo in transfusion needs.
• Rebleeding rates were similar between the cimetidine and placebo groups.
• The number of operations performed did not differ between treatment groups for gastric or duodenal ulcers.

Conclusions:

• Cimetidine therapy provided no demonstrable benefit for patients with acute upper gastrointestinal hemorrhage due to peptic ulceration.
• The drug was ineffective in reducing transfusion requirements, rebleeding, or the need for surgery.
• No specific benefit was observed in elderly patients (over 65 years).